Vertex licenses TreeFrog’s tech to upscale cell therapy manufacturing for diabetes candidates

Ver­tex will pay $25 mil­lion up­front for TreeFrog Ther­a­peu­tics’ cell man­u­fac­tur­ing tech­nol­o­gy that can help boost pro­duc­tion of its ear­ly-phase type 1 di­a­betes as­sets.

In ex­change for an ex­clu­sive li­cense for the cell pro­duc­tion tech, dubbed C-Stem, TreeFrog would al­so re­ceive an eq­ui­ty in­vest­ment from Ver­tex and up to $215 mil­lion in mile­stone pay­ments, de­pend­ing on how suc­cess­ful the tech is in scal­ing up ful­ly dif­fer­en­ti­at­ed pan­cre­at­ic islet cells that can pro­duce in­sulin.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.